Investigational Drug Information for BMS-963272
✉ Email this page to a colleague
What is the development status for investigational drug BMS-963272?
BMS-963272 is an investigational drug.
There have been 4 clinical trials for BMS-963272.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 24th 2021.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Liver Diseases, and Fatty Liver. The leading clinical trial sponsors are Bristol-Myers Squibb and [disabled in preview].
Summary for BMS-963272
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 15 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-02-24) |
| Vendors | 9 |
Recent Clinical Trials for BMS-963272
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease | Bristol-Myers Squibb | Phase 1 |
| A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin | Bristol-Myers Squibb | Phase 1 |
| A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults | Bristol-Myers Squibb | Phase 1 |
Clinical Trial Summary for BMS-963272
Top disease conditions for BMS-963272
Top clinical trial sponsors for BMS-963272
US Patents for BMS-963272
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
